Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance

Journal of Global Antimicrobial Resistance

Volumn 2, Issue 4, 2014, Pages 245-253

  Garau, Javier ^a   Nicolau, Dave P ^b   Wullt, Björn ^c   Bassetti, Matteo ^d  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b HARTFORD HOSPITAL   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antibiotic resistance; Antibiotic stewardship; Community acquired infection

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CEPHALOSPORIN; ERTAPENEM; IMIPENEM; IMMUNOSTIMULATING AGENT; PENICILLIN DERIVATIVE; PIPERACILLIN; PIVMECILLINAM;

ACUTE OTITIS MEDIA; ALTERNATIVE MEDICINE; ANTIBIOSIS; ANTIBIOTIC RESISTANCE; BACTERIAL SINUSITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED PNEUMONIA; ELECTRONIC MEDICAL RECORD; EMERGENCY WARD; ENTEROBACTERIACEAE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH STATUS; HOSPITAL PATIENT; HUMAN; IMMUNOSTIMULATION; MENINGITIS; MORBIDITY; MORTALITY; NONHUMAN; PRIMARY MEDICAL CARE; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; VACCINATION;

EID: 84916210313     PISSN: 22137165     EISSN: 22137173     Source Type: Journal    
DOI: 10.1016/j.jgar.2014.08.002     Document Type: Review

References (118)

1. B.G. Bell, F. Schellevis, E. Stobberingh, H. Goossens, and M. Pringle A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance BMC Infect Dis 14 2014 13
2. H. Goossens, M. Ferech, S. Coenen, P. Stephens, and European Surveillance of Antimicrobial Consumption Project Group Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries Clin Infect Dis 44 2007 1091 1095
3. K.V. Nguyen, N.T. Thi Do, A. Chandna, T.V. Nguyen, C.V. Pham, and P.M. Doan Antibiotic use and resistance in emerging economies: a situation analysis for Viet Nam BMC Public Health 13 2013 1158
4. E. Denes, J. Prouzergue, S. Ducroix-Roubertou, C. Aupetit, and P. Weinbreck Antibiotic prescription by general practitioners for urinary tract infections in outpatients Eur J Clin Microbiol Infect Dis 31 2012 3079 3083
5. R.P. Venekamp, M.M. Rovers, T.J.M. Verheij, M.J.M. Bonten, and A.P.E. Sachs Treatment of acute rhinosinusitis: discrepancy between guideline recommendations and clinical practice Fam Pract 29 2012 706 712
6. W.J. Fokkens, V.J. Lund, J. Mullol, C. Bachert, I. Alobid, and F. Baroody European position paper on rhinosinusitis and nasal polyps 2012 Rhinol Suppl 23 2012 1 298
7. J. van den Broek d'Obrenan, T.J. Verheij, M.E. Numans, and A.W. van der Velden Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatment J Antimicrob Chemother 69 2014 1701 1707
8. M. Andre, A. Vernby, I. Odenholt, C.S. Lundborg, I. Axelsson, and M. Eriksson Diagnosis-prescribing surveys in 2000, 2002 and 2005 in Swedish general practice: consultations, diagnosis, diagnostics and treatment choices Scand J Infect Dis 40 2008 648 654
9. European Association of Urology Guidelines, 2014 2014 http://www.uroweb.org/fileadmin/guidelines/2012-Guidelines-large-text-print-total-file.pdf [accessed 18.08.14]
10. N. van de Sande-Bruinsma, H. Grundmann, D. Verloo, E. Tiemersma, J. Monen, and H. Goossens Antimicrobial drug use and resistance in Europe Emerg Infect Dis 14 2008 http://wwwnc.cdc.gov/eid/article/14/11/07-0467 [accessed 21.08.14]
11. C.A. McNulty European Antibiotic Awareness Day 2012: general practitioners encouraged to TARGET antibiotics through guidance, education and tools J Antimicrob Chemother 67 2012 2543 2546
12. C. Costelloe, C. Metcalfe, A. Lovering, D. Mant, and A.D. Hay Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis BMJ 340 2010 c2096
13. M. Bassetti, M. Marelli, C. Temperoni, and A. Astilean New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12 2013 22
14. Infectious Diseases Society of America (IDSA), B. Spellberg, M. Blaser, R.J. Guidos, H.W. Boucher, and J.S. Bradley Combating antimicrobial resistance: policy recommendations to save lives Clin Infect Dis 52 Suppl. 5 2011 S397 S428
15. M.P. Weinstein, K.P. Klugman, and R.N. Jones Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance Clin Infect Dis 48 2009 1596 1600
16. Centers for Disease Control and Prevention (CDC) Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae - United States, 2006-2007 MMWR Morb Mortal Wkly Rep 57 2008 1353 1355
17. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Document M100-S18 2008 CLSI Wayne, PA
18. S.D. Brown, D.J. Farrell, and I. Morrissey Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study J Clin Microbiol 42 2004 4980 4987
19. R.R. Reinert, S. Reinert, M. van der Linden, M.Y. Cil, A. Al-Lahham, and P. Appelbaum Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003 Antimicrob Agents Chemother 49 2005 2903 2913
20. L. Calatayud, C. Ardanuy, E. Cercenado, A. Fenoll, E. Bouza, and R. Pallares Serotypes, clones, and mechanisms of resistance of erythromycin-resistant Streptococcus pneumoniae isolates collected in Spain Antimicrob Agents Chemother 51 2007 3240 3246
21. A.G. de la Campa, C. Ardanuy, L. Balsalobre, E. Pérez-Trallero, J.M. Marimón, and A. Fenoll Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain Emerg Infect Dis 15 2009 905 911
22. S. Simoens, J. Verhaegen, P. van Bleyenbergh, W.E. Peetermans, and M. Decramer Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones Antimicrob Agents Chemother 55 2011 3051 3053
23. S.N. Patel, A. McGeer, R. Melano, G.J. Tyrrell, K. Green, and D.R. Pillai Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada Antimicrob Agents Chemother 55 2011 3703 3708
24. K.B. Anderson, J.S. Tan, T.M. File Jr., J.R. DiPersio, B.M. Willey, and D.E. Low Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia Clin Infect Dis 37 2003 376 381
25. R. Davidson, R. Cavalcanti, J.L. Brunton, D.J. Bast, J.C. de Azavedo, and P. Kibsey Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N Engl J Med 346 2002 747 750
26. W.T. Jansen, A. Verel, M. Beitsma, J. Verhoef, and D. Milatovic Longitudinal European surveillance study of antibiotic resistance of Haemophilus influenzae J Antimicrob Chemother 58 2006 873 877
27. M. Peric, B. Bozdogan, M.R. Jacobs, and P.C. Appelbaum Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates Antimicrob Agents Chemother 47 2003 1017 1022
28. F. Zhao, G. Liu, J. Wu, B. Cao, X. Tao, and L. He Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012 Antimicrob Agents Chemother 57 2013 1521 1523
29. A. Ronald The etiology of urinary tract infection: traditional and emerging pathogens Am J Med 113 Suppl. 1A 2002 14S 19S
30. M. Tinelli, M.A. Cataldo, E. Mantengoli, C. Cadeddu, E. Cunietti, and F. Luzzaro Epidemiology and genetic characteristics of extended-spectrum β-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities J Antimicrob Chemother 67 2012 2982 2987
31. S. Auer, A. Wojna, and M. Hell Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-β-lactamase-producing Escherichia coli Antimicrob Agents Chemother 54 2010 4006 4008
32. M.N. Al-Hasan, J.E. Eckel-Passow, and L.M. Baddour Bacteremia complicating Gram-negative urinary tract infections: a population-based study J Infect 60 2010 278 285
33. L.A. Jackson, P. Benson, K.M. Neuzil, M. Grandjean, and J.L. Marino Burden of community-onset Escherichia coli bacteremia in seniors J Infect Dis 191 2005 1523 1529
34. K.B. Holten, and E.M. Onusko Appropriate prescribing of oral β-lactam antibiotics Am Fam Physician 62 2000 611 620
35. C.S. Horner, N. Abberley, M. Denton, and M.H. Wilcox Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010-2012 Epidemiol Infect 9 2013 1 5
36. C.F. van der Donk, J.H. van de Bovenkamp, E.I. De Brauwer, P. De Mol, K.H. Feldhoff, and W.M. Kalka-Moll Antimicrobial resistance and spread of multi drug resistant Escherichia coli isolates collected from nine urology services in the Euregion Meuse-Rhine PLOS ONE 7 2012 e47707
37. G. Kamenski, G. Wagner, S. Zehetmayer, W. Fink, W. Spiegel, and K. Hoffmann Antibacterial resistances in uncomplicated urinary tract infections in women: ECO. SENS II data from primary health care in Austria BMC Infect Dis 12 2012 222
38. G.V. Sanchez, R.N. Master, J.A. Karlowsky, and J.M. Bordon In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010 Antimicrob Agents Chemother 56 2012 2181 2183
39. A. Vellinga, S. Tansey, B. Hanahoe, K. Bennett, A.W. Murphy, and M. Cormican Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with Escherichia coli: a multilevel model J Antimicrob Chemother 67 2012 2523 2530
40. S. Bouchillon, D.J. Hoban, R. Badal, and S. Hawser Fluoroquinolone resistance among Gram-negative urinary tract pathogens: global SMART Program results, 2009-2010 Open Microbiol J 6 2012 74 78
41. A. Ostholm-Balkhed, M. Tärnberg, M. Nilsson, L.E. Nilsson, H. Hanberger, and A. Hällgren Travel-associated faecal colonization with ESBL-producing Enterobacteriaceae: incidence and risk factors J Antimicrob Chemother 68 2013 2144 2153
42. A. Pallett, and K. Hand Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria J Antimicrob Chemother 65 Suppl. 3 2010 iii25 iii33
43. J. Oteo, V. Bautista, N. Lara, O. Cuevas, M. Arroyo, and S. Fernández Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum β-lactamase (ESBL)-producing Escherichia coli J Antimicrob Chemother 65 2010 2459 2463
44. M.H. Kollef Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit Crit Care 9 2005 459 464
45. L. Mody, S.F. Bradley, A. Galecki, R.N. Olmsted, J.T. Fitzgerald, and C.A. Kauffman Conceptual model for reducing infections and antimicrobial resistance in skilled nursing facilities: focusing on residents with indwelling devices Clin Infect Dis 52 2011 654 661
46. M. Juthani-Mehta, and V.J. Quagliarello Infectious diseases in the nursing home setting: challenges and opportunities for clinical investigation Clin Infect Dis 51 2010 931 936
47. R.L. Stuart, J. Wilson, E. Bellaard-Smith, R. Brown, L. Wright, and S. Vandergraaf Antibiotic use and misuse in residential aged care facilities Intern Med J 42 2012 1145 1149
48. T.H. Dellit, R.C. Owens, J.E. McGowan Jr., D.N. Gerding, R.A. Weinstein, and J.P. Burke Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship Clin Infect Dis 44 2007 159 177
49. G. Barlow, and D. Nathwani Is antibiotic resistance a problem? A practical guide for hospital clinicians Postgrad Med J 81 2005 680 692
50. C. MacDougall, and R.E. Polk Antimicrobial stewardship programs in health care systems Clin Microbiol Rev 18 2005 638 656
51. M.K. Joung, J.A. Lee, S.Y. Moon, H.S. Cheong, E.J. Joo, and Y.E. Ha Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia Crit Care 15 2011 R79
52. S.T. Micek, E.C. Welch, J. Khan, M. Pervez, J.A. Doherty, and R.M. Reichley Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis Antimicrob Agents Chemother 54 2010 1742 1748
53. J. Morel, J. Casoetto, R. Jospé, G. Aubert, R. Terrana, and A. Dumont De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit Crit Care 14 2010 R225
54. E. Toubes, K. Singh, D. Yin, R. Lyu, N. Glick, and L. Russell Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? Clin Infect Dis 36 2003 724 730
55. T.P. Lodise, P.S. McKinnon, V.H. Tam, and M.J. Rybak Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center Clin Infect Dis 34 2002 922 929
56. M.A. Rogers, L. Mody, C. Chenoweth, S.R. Kaufman, and S. Saint Incidence of antibiotic-resistant infection in long-term residents of skilled nursing facilities Am J Infect Control 36 2008 472 475
57. R.K. Pelz, P.A. Lipsett, S.M. Swoboda, M. Diener-West, N.R. Powe, and R.G. Brower Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes Intensive Care Med 28 2002 692 697
58. X. Song, A. Srinivasan, D. Plaut, and T.M. Perl Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs Infect Control Hosp Epidemiol 24 2003 251 256
59. A. Kumar, D. Roberts, K.E. Wood, B. Light, J.E. Parrillo, and S. Sharma Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 34 2006 1589 1596
60. G. Taubes Collateral damage. The rise of resistant C. difficile Science 321 2008 360
61. E. Dubberke Strategies for prevention of Clostridium difficile infection J Hosp Med 7 Suppl. 3 2012 S14 S17
62. Y. Hayashi, and D.L. Paterson Strategies for reduction in duration of antibiotic use in hospitalized patients Clin Infect Dis 52 2011 1232 1240
63. E. Avdic, L.A. Cushinotto, A.H. Hughes, A.R. Hansen, L.E. Efird, and J.G. Bartlett Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia Clin Infect Dis 54 2012 1581 1587
64. G. Capellier, H. Mockly, C. Charpentier, D. Annane, G. Blasco, and T. Desmettre Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment PLOS ONE 7 2012 e41290
65. D.J. Hoban Antibiotics and collateral damage Clin Cornerstone Suppl. 3 2003 S12 S20
66. D.L. Paterson 'Collateral damage' from cephalosporin or quinolone antibiotic therapy Clin Infect Dis 38 Suppl. 4 2004 S341 S345
67. K. Gupta, T.M. Hooton, K.G. Naber, B. Wullt, R. Colgan, and L.G. Miller International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases Clin Infect Dis 52 2011 e103 e120
68. E.J. Goldstein Beyond the target pathogen: ecological effects of the hospital formulary Curr Opin Infect Dis 24 Suppl. 1 2011 S21 S31
69. Y. Carmeli, S.K. Lidji, E. Shabtai, S. Navon-Venezia, and M.J. Schwaber The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study Diagn Microbiol Infect Dis 70 2011 367 372
70. C. Thomas, and T.V. Riley Restriction of third generation cephalosporin use reduces the incidence of Clostridium difficile-associated diarrhoea in hospitalised patients Commun Dis Intell Q Rep 27 Suppl. 2003 S28 S31
71. L. Valiquette, B. Cossette, M.P. Garant, H. Diab, and J. Pépin Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain Clin Infect Dis 45 Suppl. 2 2007 S112 S121
72. M. Woodhead, F. Blasi, S. Ewig, J. Garau, G. Huchon, and M. Ieven Guidelines for the management of adult lower respiratory tract infections - full version Clin Microbiol Infect 17 Suppl. 6 2011 E1 E59
73. L.A. Mandell, R.G. Wunderink, A. Anzueto, J.G. Bartlett, G.D. Campbell, and N.C. Dean Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults Clin Infect Dis 44 Suppl. 2 2007 S27 S72
74. K.L. Nichol, L. Baken, J. Wuorenma, and A. Nelson The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease Arch Intern Med 159 1999 2437 2442
75. E.P. Galiza, and P.T. Heath Pneumococcal conjugate vaccines: a review Minerva Med 98 2007 131 143
76. M.H. Kyaw, R. Lynfield, W. Schaffner, A.S. Craig, J. Hadler, and A. Reingold Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae N Engl J Med 354 2006 1455 1463
77. C.G. Whitney, M.M. Farley, J. Hadler, L.H. Harrison, N.M. Bennett, and R. Lynfield Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N Engl J Med 348 2003 1737 1746
78. G. Lanzilli, R. Falchetti, A. Cottarelli, A. Machi, D. Ungheri, and M.P. Fuggetta In vivo effect of an immunostimulating bacterial lysate on human B lymphocytes Int J Immunopathol Pharmacol 19 2006 551 559
79. R.O. Darouiche, and R.A. Hull Bacterial interference for prevention of urinary tract infection Clin Infect Dis 55 2012 1400 1407
80. A.W. van der Velden, E.J. Pijpers, M.M. Kuyvenhoven, S.K. Tonkin-Crine, P. Little, and T.J. Verheij Effectiveness of physician-targeted interventions to improve antibiotic use for respiratory tract infections Br J Gen Pract 62 2012 e801 e807
81. C. Pulcini, and I.C. Gyssens How to educate prescribers in antimicrobial stewardship practices Virulence 4 2013 192 202
82. R.L. Jump, D.M. Olds, N. Seifi, G. Kypriotakis, L.A. Jury, and E.P. Peron Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic use Infect Control Hosp Epidemiol 33 2012 1185 1192
83. D. Nathwani, J. Sneddon, W. Malcolm, C. Wiuff, A. Patton, and S. Hurding Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme Int J Antimicrob Agents 38 2011 16 26
84. L.Y. Hsu, A.L. Kwa, D.C. Lye, M.P. Chlebicki, T.Y. Tan, and M.L. Ling Reducing antimicrobial resistance through appropriate antibiotic usage in Singapore Singapore Med J 49 2008 749 755
85. S. Sethi, and T.F. Murphy Infection in the pathogenesis and course of chronic obstructive pulmonary disease N Engl J Med 359 2008 2355 2365
86. J. Vestbo, S.S. Hurd, A.G. Agustí, P.W. Jones, C. Vogelmeier, and A. Anzueto Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
87. P.J. Poole, E. Chacko, R.W. Wood-Baker, and C.J. Cates Influenza vaccine for patients with chronic obstructive pulmonary disease Cochrane Database Syst Rev 1 2006 CD002733
88. I. Alfageme, R. Vazquez, N. Reyes, J. Muñoz, A. Fernández, and M. Hernandez Clinical efficacy of anti-pneumococcal vaccination in patients with COPD Thorax 61 2006 189 195
89. F. Braido, F. Tarantini, V. Ghiglione, G. Melioli, and G.W. Canonica Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections Int J Chron Obstruct Pulmon Dis 2 2007 335 345
90. M. Cazzola, P. Rogliani, and G. Curradi Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view Respir Med 102 2008 321 327
91. J. Mauël Stimulation of immunoprotective mechanisms by OM-85 BV. A review of results from in vivo and in vitro studies Respiration 61 Suppl. 1 1994 8 15
92. A. Rozy, and J. Chorostowska-Wynimko Bacterial immunostimulants - mechanism of action and clinical application in respiratory diseases Pneumonol Alergol Pol 76 2008 353 359
93. U.B. Schaad OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review World J Pediatr 6 2010 5 12
94. M.D. Gutiérrez-Tarango, and A. Berber Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months Chest 119 2001 1742 1748
95. U.B. Schaad, R. Mütterlein, H. Goffin BV-Child Study Group Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study Chest 122 2002 2042 2049
96. C.H. Razi, K. HarmancI, A. AbacI, O. Özdemir, S. HIzlI, and R. Renda The immunostimulant OM-85 BV prevents wheezing attacks in preschool children J Allergy Clin Immunol 126 2010 763 769
97. J.V. Jara-Pérez, and A. Berber Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial Clin Ther 22 2000 748 759
98. B. Heintz, W.W. Schlenter, R. Kirsten, and K. Nelson Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis - a multi-centric, placebo-controlled, double-blind study Int J Clin Pharmacol Ther Toxicol 27 1989 530 534
99. M. Solèr, R. Mütterlein, G. Cozma Swiss-German OM-85 Study Group Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease Respiration 74 2007 26 32
100. B. Orcel, B. Delclaux, M. Baud, and J.P. Derenne Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis Eur Respir J 7 1994 446 452
101. J.P. Collet, P. Shapiro, P. Ernst, T. Renzi, T. Ducruet, and A. Robinson Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant Am J Respir Crit Care Med 156 1997 1719 1724
102. J. Li, J.P. Zheng, J.P. Yuan, G.Q. Zeng, N.S. Zhong, and C.Y. Lin Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease Chin Med J (Engl) 117 2004 828 834
103. K.E. Sivick, and H.L. Mobley Waging war against uropathogenic Escherichia coli: winning back the urinary tract Infect Immun 78 2010 568 585
104. F.M. Wagenlehner, A. Pilatz, P. Waliszewski, W. Weidner, and T.E. Johansen Reducing infection rates after prostate biopsy Nat Rev Urol 11 2014 80 86
105. S. Hansson, U. Jodal, K. Lincoln, and C. Svanborg-Edén Untreated asymptomatic bacteriuria in girls: II - Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections BMJ 298 1989 856 859
106. T. Cai, S. Mazzoli, N. Mondaini, F. Meacci, G. Nesi, and C. D'Elia The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 55 2012 771 777
107. R.O. Darouiche, J.I. Thornby, C. Cerra-Stewart, W.H. Donovan, and R.A. Hull Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial Clin Infect Dis 41 2005 1531 1534
108. F. Sundén, L. Håkansson, E. Ljunggren, and B. Wullt Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying J Urol 184 2010 179 185
109. A.E. Stapleton, M. Au-Yeung, T.M. Hooton, D.N. Fredricks, P.L. Roberts, and C.A. Czaja Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection Clin Infect Dis 52 2011 1212 1217
110. R. Raz, and W.E. Stamm A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections N Engl J Med 329 1993 753 756
111. R.G. Jepson, G. Williams, and J.C. Craig Cranberries for preventing urinary tract infections Cochrane Database Syst Rev 10 2012 CD001321
112. M.F. Lorenzo-Gómez, B. Padilla-Fernández, F.J. García-Criado, J.A. Mirón-Canelo, A. Gil-Vicente, and A. Nieto-Huertos Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics Int Urogynecol J 24 2013 127 134
113. K.G. Naber, Y.H. Cho, T. Matsumoto, and A.J. Schaeffer Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis Int J Antimicrob Agents 33 2009 111 119
114. C.C. Schulman, A. Corbusier, H. Michiels, and H.J. Taenzer Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study J Urol 150 1993 917 921
115. H.W. Bauer, S. Alloussi, G. Egger, H.M. Blümlein, G. Cozma, and C.C. Schulman A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections Eur Urol 47 2005 542 548 discussion 548
116. B. Lettgen Prevention of recurrent urinary tract infections in female children: OM-89 immunotherapy compared with nitrofurantoin prophylaxis in a randomized pilot study Curr Ther Res 57 1996 464 475
117. R. Baertschi, J.A. Balmer, S.B. Eduah, A. Liechti, D. Lurie, and H. Schams Bacterial extract for the prevention of recurrent urinary tract infection in pregnant women: a pilot study Int J Immunother 19 2003 25 31
118. G. Popa, K.-D. Lauber, H. Rothe, and E. Rugendorff Recurrent postmenopausal urinary tract infections. Efficacy of oral immunotherapy with E. coli fractions MMW 1996 3 6